


N,N'-Dioxide–Scandium(III)-Catalyzed Asymmetric Aza-Friedel–Crafts Reaction of Sesamol with Aldimines

Sha Bai, Yuting Liao, Lili Lin, Weiwei Luo, Xiaohua Liu, and Xiaoming Feng*

Key Laboratory of Green Chemistry & Technology, Ministry of Education, College of Chemistry, Sichuan University, Chengdu 610064, P. R. China

S Supporting Information



ABSTRACT: A highly efficient aza-Friedel–Crafts reaction of sesamol with aldimines has been realized by using a chiral *N,N'*-dioxide–scandium(III) complex as the catalyst. A series of corresponding bioactive chiral α -amino-sesamols were obtained in moderate to good yields (up to 97%) with excellent enantioselectivities (up to 97% *ee*). Furthermore, the control experiments were conducted to provide fundamental insights into the mechanism of the reaction.

Sesamol, a natural organic compound derived from sesame oil, is a crucial fragment found in a number of biologically active molecules and natural products.¹ Meanwhile, chiral α -amino-substituted sesamol derivatives have emerged as ubiquitous antibacterial and antitumor pharmaceuticals, such as (–)-fumimycin, (+)-FRDA drug, cyanocycline, and oxazapodophyllotoxin I (Figure 1).² A facile way to construct




Figure 1. Examples of amino-sesamol derivatives.

these α -amino-sesamols in enantiomerically enriched form is the asymmetric aza-Friedel–Crafts (F–C) reaction³ of sesamol with imines. Notably, the nucleophiles⁴ toward the asymmetric aza-Friedel–Crafts reaction with imines mainly focused on indoles,⁵ pyrroles,⁶ and naphthols,⁷ but limited research has been conducted in sesamols.

Very recently, Chimni⁸ et al. reported the asymmetric aza-Friedel–Crafts reaction of sesamol with aldimines using 6'-OH *Cinchona* alkaloids^{7,8} as the organocatalyst, yet moderate to high enantioselectivities were obtained (62–95% *ee*). For the importance of chiral α -amino-substituted sesamol derivatives, the development of new catalyst systems for the asymmetric aza-Friedel–Crafts reaction³ of sesamol with imines with higher reactivity and enantioselectivity is desirable. We envisioned that the chiral *N,N'*-dioxide/metal complex catalysts developed by our group might be competent, because both of the oxygen atoms on sesamol and imines could coordinate with the metal center strongly to ensure a better chiral environment (Scheme 1). Herein, we made our efforts to develop a highly efficient chiral *N,N'*-dioxide–scandium(III) catalyst⁹ system for the asymmetric aza-Friedel–Crafts reaction of sesamol with aldimines.

Our initial investigation began with the aza-Friedel–Crafts reaction of *N*-Ts phenyl imine (1a) with sesamol (2) as a model reaction. First, several chiral Lewis acid catalysts generated in situ from metal salts and *L*-proline derived *N,N'*-dioxide L1 were evaluated in CH₂Cl₂ at 0 °C for 30 h (Table 1). The reaction proceeded sluggishly in the presence of most of the metal sources evaluated (for more details, see the Supporting Information). For example, the complex of Cu(OTf)₂ or Fe(CLO₄)₂·6H₂O gave only less than 10% yield with 13% *ee* and 9% *ee*, respectively, while the complex of La(OTf)₃ gave a racemic product in 20% yield (Table 1, entries 1, 2, and 3). Pleasingly, the L1–Sc(OTf)₃ complex promoted the reaction with moderate enantioselectivity (50% *ee*), though the yield was still low (27% yield, Table 1, entry 4). In order to

Received: August 30, 2014

Published: October 16, 2014

Scheme 1. Catalytic Asymmetric Aza-Friedel–Crafts Reaction of Sesamol with Imines




Table 1. Evaluation of the Reaction Conditions

entry ^a	L	metal	solvent	yield ^b (%)	ee ^c (%)
1	L1	Cu(OTf) ₂	CH ₂ Cl ₂	8	13
2	L1	Fe(ClO ₄) ₂ ·6H ₂ O	CH ₂ Cl ₂	7	9
3	L1	La(OTf) ₃	CH ₂ Cl ₂	20	0
4	L1	Sc(OTf) ₃	CH ₂ Cl ₂	27	50
5	L2	Sc(OTf) ₃	CH ₂ Cl ₂	16	25
6	L3	Sc(OTf) ₃	CH ₂ Cl ₂	35	67
7	L4	Sc(OTf) ₃	CH ₂ Cl ₂	21	55
8	L5	Sc(OTf) ₃	CH ₂ Cl ₂	16	47
9	L3	Sc(OTf) ₃	PhCH ₃	37	77
10 ^d	L3	Sc(OTf) ₃	PhCH ₃	36	91
11 ^{d,e}	L3	Sc(OTf) ₃	PhCH ₃	58	93
12 ^{d,e,f,g}	L3	Sc(OTf) ₃	PhCH ₃	93	94
13 ^{d,e,f,g}	L6	Sc(OTf) ₃	PhCH ₃	90	−94

^aUnless otherwise noted, the reactions were performed with L3/Sc(OTf)₃ (1:1, 10 mol %), aldimine **1a** (0.10 mmol), and sesamol **2** (0.10 mmol) in solvent (0.5 mL) at 0 °C for 30 h. ^bIsolated yield. ^cDetermined by chiral HPLC analysis (Chiralcel ID). ^d3-BrC₆H₄CO₂H (10 mol %) was used. ^e3 μL of water was added. ^fIn 0.1 mL of toluene. ^gReaction was carried out with L/Sc(OTf)₃ (1.3/1), and the reaction time was 48 h.

further improve the reactivity and enantioselectivity of the reaction, various chiral *N,N'*-dioxide ligands in coordination with Sc(OTf)₃ were surveyed (Figure 2). Both the chiral backbone and the amide moiety of the ligand played a key role in the enantioselectivity. When the amide moiety was replaced by an aliphatic 1-adamantyl group, the enantioselectivity as well





Figure 2. Chiral ligands used in this study.

as the reactivity obviously dropped (16% yield and 25% ee; Table 1, entry 5 vs entry 4). In addition, steric hindrance of the amide moiety on the ligand was crucial for the enantioselectivity, and more hindered ligand **L3** improved the yield to 35% and the ee to 67% (Table 1, entry 6). As for the amino acid backbone, *L*-proline derived *N,N'*-dioxide **L3** was superior to (*S*)-pipercolic acid derived **L4** and *L*-ramipril derived **L5** (Table 1, entry 6 vs entries 7 and 8). Solvent investigation revealed that the reaction underwent smoothly in toluene with the increased ee to 77% (Table 1, entry 9). To our delight, the addition of a catalytic amount of 3-bromobenzoic acid to the system could further improve the enantioselectivity to 91% ee (Table 1, entry 10), which implied that the acid might participate in the chiral control step. Interestingly, when a small amount of water¹⁰ existed, the yield was improved significantly to 58% with the ee increased slightly to 93% (Table 1, entry 11). Eventually, the optimized conditions were established with the outcomes of 93% yield with 94% ee when the concentration of substrates was increased to 1 × 10^{−3} mol/mL and the ratio of **L3**/Sc(OTf)₃ was adjusted to 1.3/1 along with the prolonged reaction time to 48 h (Table 1, entry 12). In addition, the opposite enantiomer was directly obtained by using the *D*-proline derived **L6**–Sc(OTf)₃ (Table 1, entry 13). Furthermore, it was noteworthy that the overall operation was easily accessible including air and moisture tolerant.

With the optimized conditions in hand, various *N*-Ts phenyl imines were examined. As summarized in Table 2, regardless of the electron-donating or electron-withdrawing substituents on the aromatic ring of **1**, high enantioselectivities (89–97% ee) were obtained. The yields of the products were dependent on the position of the substituents. Generally, substituents on the *meta*-position of the aromatic ring of **1** presented better yields than the *ortho*- or *para*-substituted ones (Table 2, entry 3 vs entries 2 and 4; entry 6 vs entries 5 and 7). Remarkably, heteroaromatic 2-furyl aldimine **1m** was tolerated, generating the desired product in 80% yield and 86% ee (Table 2, entry 13). The 2-thienyl aldimine **1n** transformed to **3n** in reduced yield (32%) and 83% ee (Table 2, entry 14). Ring-fused 2-naphthyl aldimine **1o** was also a suitable substrate to generate the **3o** in 53% yield and 86% ee (Table 2, entry 15). When the protected group was changed to *Bs* or a more electron-withdrawing 4-chloro-phenylsulfonyl group, the reactivity as well as the enantioselectivity maintained (Table 2, entries 16 and 17). Unfortunately, the reaction of aliphatic aldimines performed sluggishly.

The absolute configuration of the α-amino-substituted sesamol **3f** was unambiguously determined to be *R* by single-crystal X-ray diffraction analysis of the corresponding *t*-butoxycarbonyl-protected derivative **4**.¹¹

Table 2. Substrate Scope of the Asymmetric Aza-Friedel–Crafts Reaction of Aldimines




entry ^a	Ar	R ¹	yield ^b (%)	ee ^c (%)
1 ^d	Ph	Ts	3a: 93	94
2	2-MeC ₆ H ₄	Ts	3b: 63	97
3	3-MeC ₆ H ₄	Ts	3c: 80	93
4	4-MeC ₆ H ₄	Ts	3d: 72	91
5 ^d	2-FC ₆ H ₄	Ts	3e: 83	96
6 ^d	3-FC ₆ H ₄	Ts	3f: 97	95
7 ^d	4-FC ₆ H ₄	Ts	3g: 90	95
8 ^d	3-ClC ₆ H ₄	Ts	3h: 91	96
9	4-ClC ₆ H ₄	Ts	3i: 75	94
10	3-BrC ₆ H ₄	Ts	3j: 64	92
11	3-F ₃ CC ₆ H ₄	Ts	3k: 90	96
12	4-F ₃ CC ₆ H ₄	Ts	3l: 71	89
13 ^e	2-furyl	Ts	3m: 80	86
14	2-thienyl	Ts	3n: 32	83
15	2-naphthyl	Ts	3o: 53	86
16	C ₆ H ₅	Bs	3p: 85	92
17	C ₆ H ₅	4-ClC ₆ H ₄ SO ₂	3q: 80	95

^aUnless otherwise noted, the reactions were performed with **1** (0.20 mmol), **2** (0.20 mmol), L3/Sc(OTf)₃ (1.3:1, 10 mol %), PhCH₃ (0.2 mL), 3-BrC₆H₄CO₂H (0.02 mmol), and H₂O (3 μL) in 0 °C for 72 h. ^bIsolated yield. ^cDetermined by HPLC on a chiral stationary phase. ^dThe reaction time was 48 h. ^eDetermined by chiral HPLC analysis of the *N*-Boc-protected product **3m**.

To evaluate the synthetic potential of the catalyst system, a gram-scale synthesis of α -amino-sesamol **3a** was carried out. In the presence of 10 mol % of L3–Sc(OTf)₃, 5.0 mmol of *N*-Ts phenyl imine **1a** (1.295 g) reacted with 1.0 equiv of sesamol **2** (0.690 g), generating the desired product **3a** in 89% yield (1.768 g) and 92% ee (Scheme 2).

Scheme 2. Scaled-Up Version of the Reaction



In order to gain an insight into the reaction mechanism, the relationship between the ee of the ligand L3 and that of the product **3a** was investigated (see the Supporting Information for details). A linear effect was observed, which suggested that the monomeric complex might function as the most active and effective catalytic species.¹²

Then, ¹H NMR analysis was carried out to provide a further insight on the catalytic process. As shown by the ¹H NMR spectra (Figure 3), the proton signal of the hydroxyl group on sesamol **2** was obviously shifted downfield from 4.77 to 5.30 ppm, which corresponded to the coordination of the hydroxyl group on the sesamol to the Sc³⁺. To supplement, the catalytic compositions were investigated by using ESI-MS (Figure 4). The spectra of the sample obtained from the mixture of L3–




Figure 3. ¹H NMR spectra of the OH group of sesamol **2** in diverse conditions: (1) **2** in CDCl₃; (2) Sc(OTf)₃/L3/2 (1/1.3/1) in CDCl₃.




Figure 4. ESI-MS spectra of solutions of the catalyst-substrate: (a) L3–Sc³⁺–2; (b) L3–Sc³⁺–2–1h-additives.

Sc(OTf)₃ and sesamol **2** revealed an ion at *m/z* 1035.4584, which was assigned to the intermediate [(L3–H)[–] + Sc³⁺ + TfO[–] + 2]⁺. Upon addition of aldimine **2h** and additives for 48 h, the ion at *m/z* 1328.5186 was gained, which corresponded to the intermediate [(L3–H)[–] + Sc³⁺ + TfO[–] + 3h]⁺.

On the basis of the experiments and previous reports,^{9d,f} a catalytic cycle with a transition-state model was proposed in Figure 5. First, the catalyst¹³ generated in situ from L3 and Sc(OTf)₃ coordinated with the hydroxyl group of **2**¹⁴ to give intermediate **T1**. Then, **T1** coordinated with the oxygen atom of the sulfonyl group because of the oxygen affinity characteristic of scandium,¹⁵ accompanying with the hydrogen bonding¹⁶ between the nitrogen atom of aldimine **1** and the hydrogen atom of 3-bromobenzoic acid (**T2**). The *Re* face of aldimine **1** was shielded by the neighboring 2,4,6-triisopropylphenyl group. Therefore, the nucleophile **2** preferably attacked electrophile **1** from the *Si*-face to generate the corresponding *R*-




Figure 5. Proposed catalytic cycle.

configured product. Additionally, the C–C bond formation disrupted the aromaticity of the sesamol (**T3**). After attracting a proton to form 3-bromobenzoic acid, the aromaticity was reestablished (**T4**). In the last step, the desired product **3** was dissociated and the catalyst was regenerated.

In summary, we have developed an efficient asymmetric azo-Friedel–Crafts reaction of aldimines with sesamol catalyzed by a chiral *N,N'*-dioxide–Sc(III) complex. A wide range of α -amino-sesamols were obtained in good yields (up to 97%) with good to excellent enantioselectivities (up to 97% *ee*) under mild reaction conditions. On the basis of the experiments and the previous work, a possible catalytic cycle was proposed.

EXPERIMENTAL SECTION

General Remarks. Reactions were carried out using commercially available reagents in oven-dried apparatus. Toluene was directly distilled before use. Enantiomeric excesses (*ee*) were determined by HPLC analysis using the corresponding commercial chiral column as stated in the experimental procedures at 23 °C with a UV detector at 254 nm. Optical rotations were reported as follows: $[\alpha]_D^{25}$ (*c* g/100 mL, in solvent). ¹H NMR spectra were recorded on commercial instruments (400 MHz). ¹³C NMR spectra was collected on commercial instruments (100 MHz) with complete proton decoupling. HRMS was recorded on a commercial apparatus (ESI Source).

General Procedure for the Catalytic Asymmetric Azo-Friedel–Crafts Reaction. A solution of *N,N'*-dioxide **L3** (18.2 mg, 0.026 mmol), Sc(OTf)₃ (10.0 mg, 0.020 mmol), and 3-BrC₆H₄CO₂H (4.0 mg, 0.020 mmol) in 0.2 mL of PhCH₃ was stirred at 30 °C for 0.5 h. Then, sesamol **2** (0.20 mmol), H₂O (3 μ L), and aldimine **1** (0.20 mmol) were added. The mixture was stirred at 0 °C for 48 or 72 h. The reaction mixture was purified via flash chromatography (CH₂Cl₂/EtOAc = 20/1) on silica gel to afford the desired product. The enantiomeric excess (*ee*) was determined by high-performance liquid chromatography (HPLC).

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(phenyl)methyl)-4-methylbenzenesulfonamide **3a**. Yield: 36.9 mg, 93%, yellow oil.

HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, λ = 254 nm), *t*_r(major) = 13.94 min, *t*_r(minor) = 19.47 min, *ee* = 94%. $[\alpha]_D^{16.3}$ = 40.0 (*c* = 0.80, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.54 (d, *J* = 8.3 Hz, 2H), 7.23–7.12 (m, 5H), 7.07 (d, *J* = 8.1 Hz, 2H), 6.26 (d, *J* = 6.4 Hz, 3H), 6.00 (d, *J* = 8.7 Hz, 1H), 5.78 (s, 2H), 5.54 (d, *J* = 8.7 Hz, 1H), 2.32 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 148.2, 147.5, 143.3, 141.1, 139.8, 136.7, 129.3, 128.4, 127.4, 127.1, 126.9, 118.1, 108.6, 101.2, 99.1, 58.4, 21.4. HRMS (ESI-TOF): Calcd for C₂₁H₁₉NO₅S [M + Na]⁺ 420.0876, Found: 420.0880.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(*o*-tolyl)methyl)-4-methylbenzenesulfonamide **3b**. Yield: 25.9 mg, 63%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, λ = 254 nm), *t*_r(major) = 10.52 min, *t*_r(minor) = 19.05 min, *ee* = 97%. $[\alpha]_D^{24.5}$ = 15.0 (*c* = 0.99, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.55 (d, *J* = 7.9 Hz, 2H), 7.20–6.94 (m, 6H), 6.38 (s, 1H), 6.22 (s, 1H), 6.13 (s, 1H), 5.86 (d, *J* = 7.7 Hz, 1H), 5.79 (d, *J* = 6.2 Hz, 2H), 5.36 (d, *J* = 7.6 Hz, 1H), 2.33 (s, 3H), 2.12 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 149.0, 147.8, 143.5, 141.4, 136.8, 136.4, 135.7, 130.7, 129.3, 127.6, 127.2, 126.5, 126.0, 117.6, 107.8, 101.2, 99.4, 54.0, 21.5, 19.1. HRMS (ESI-TOF): Calcd for C₂₂H₂₁NO₅S [M + Na]⁺ 434.1033, Found: 434.1034.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(*m*-tolyl)methyl)-4-methylbenzenesulfonamide **3c**. Yield: 32.9 mg, 80%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75:25, flow rate = 1.0 mL/min, λ = 254 nm), *t*_r(major) = 11.78 min, *t*_r(minor) = 15.66 min, *ee* = 93%. $[\alpha]_D^{24.5}$ = 14.8 (*c* = 0.85, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.55 (d, *J* = 8.0 Hz, 2H), 7.08 (dd, *J* = 7.3, 4.7 Hz, 3H), 6.98 (d, *J* = 7.5 Hz, 1H), 6.93 (s, 2H), 6.28 (d, *J* = 6.8 Hz, 2H), 6.23–5.98 (m, 1H), 5.94–5.72 (m, 3H), 5.53 (d, *J* = 8.5 Hz, 1H), 2.33 (s, 3H), 2.21 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 148.3, 147.5, 143.3, 141.2, 139.5, 138.1, 136.8, 129.3, 128.3, 128.2, 127.6, 127.2, 123.9, 118.3, 108.6, 101.2, 99.2, 58.2, 21.4. HRMS (ESI-TOF): Calcd for C₂₂H₂₁NO₅S [M + Na]⁺ 434.1033, Found: 434.1033.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(*p*-tolyl)methyl)-4-methylbenzenesulfonamide **3d**. Yield: 29.6 mg, 72%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, λ = 254 nm), *t*_r(major) = 10.41 min, *t*_r(minor) = 13.81 min, *ee* = 91%.

$[\alpha]_{\text{D}}^{26.0} = 20.2$ ($c = 0.70$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.54$ (d, $J = 8.2$ Hz, 2H), 7.12–6.96 (m, 6H), 6.33–6.16 (m, 3H), 5.94 (d, $J = 8.0$ Hz, 1H), 5.78 (s, 2H), 5.50 (d, $J = 8.5$ Hz, 1H), 2.32 (s, 3H), 2.26 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.2$, 147.5, 143.3, 141.1, 137.1, 136.8, 129.3, 129.1, 127.2, 126.8, 118.3, 108.6, 101.1, 99.1, 58.2, 21.4, 21.0. HRMS (ESI-TOF): Calcd for $\text{C}_{22}\text{H}_{21}\text{NO}_5\text{S} [\text{M} + \text{Na}]^+$ 434.1033, Found: 434.1044.

N-((2-Fluorophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3e**. Yield: 34.5 mg, 83%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 17.23 min, t_r (minor) = 25.53 min, $ee = 96\%$. $[\alpha]_{\text{D}}^{16.3} = 23.5$ ($c = 0.60$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.57$ (d, $J = 8.2$ Hz, 2H), 7.22 (d, $J = 7.6$ Hz, 1H), 7.19–7.11 (m, 1H), 7.08 (d, $J = 8.0$ Hz, 2H), 6.96 (t, $J = 7.2$ Hz, 1H), 6.87 (dd, $J = 10.0$, 8.8 Hz, 1H), 6.39 (s, 1H), 6.34 (s, 1H), 6.30 (s, 1H), 5.93 (d, $J = 8.8$ Hz, 1H), 5.81 (d, $J = 10.3$ Hz, 3H), 2.32 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 159.78$ (d, $J = 247.4$ Hz), 148.66, 147.82, 143.53, 141.20, 136.30, 129.33, 129.24, 128.85 (d, $J = 4.0$ Hz), 127.2, 126.4 (d, $J = 12.1$ Hz), 124.1 (d, $J = 4.0$ Hz), 117.0, 115.5 (d, $J = 22.2$ Hz), 107.9, 101.2, 99.2, 53.2, 21.4. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}\text{FNO}_5\text{S} [\text{M} + \text{Na}]^+$ 438.0782, Found: 438.0783.

N-((3-Fluorophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3f**. Yield: 40.3 mg, 97%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 8.37 min, t_r (minor) = 10.01 min, $ee = 95\%$. $[\alpha]_{\text{D}}^{24.5} = 24.7$ ($c = 1.03$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.55$ (d, $J = 8.2$ Hz, 2H), 7.17 (td, $J = 8.3$, 4.0 Hz, 1H), 7.10 (d, $J = 8.1$ Hz, 2H), 6.97 (d, $J = 7.7$ Hz, 1H), 6.92–6.79 (m, 2H), 6.26 (d, $J = 17.3$ Hz, 2H), 6.19 (s, 1H), 6.03 (d, $J = 8.9$ Hz, 1H), 5.81 (s, 2H), 5.50 (d, $J = 8.9$ Hz, 1H), 2.34 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 162.7$ (d, $J = 247.4$ Hz), 148.0, 147.7, 143.5, 142.6 (d, $J = 7.1$ Hz), 141.2, 136.6, 129.8 (d, $J = 9.1$ Hz), 129.4, 127.1, 122.5 (d, $J = 3.0$ Hz), 117.6, 114.2 (d, $J = 21.2$ Hz), 114.0 (d, $J = 23.2$ Hz), 108.6, 101.3, 99.0, 58.0, 21.4. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}\text{FNO}_5\text{S} [\text{M} + \text{Na}]^+$ 438.0782, Found: 438.0793.

N-((4-Fluorophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3g**. Yield: 37.4 mg, 90%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 8.32 min, t_r (minor) = 10.91 min, $ee = 95\%$. $[\alpha]_{\text{D}}^{16.3} = 27.4$ ($c = 0.68$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.54$ (d, $J = 8.3$ Hz, 2H), 7.17–7.07 (m, 4H), 6.88 (t, $J = 8.7$ Hz, 2H), 6.28 (s, 1H), 6.24 (s, 1H), 6.12 (s, 1H), 5.95 (d, $J = 8.8$ Hz, 1H), 5.82 (s, 2H), 5.51 (d, $J = 8.6$ Hz, 1H), 2.35 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 162.0$ (d, $J = 247.4$ Hz), 148.0, 147.7, 143.5, 141.3, 136.6, 135.6 (d, $J = 3.0$ Hz), 129.3, 128.6 (d, $J = 8.1$ Hz), 127.1, 117.8, 115.2 (d, $J = 21.2$ Hz), 108.6, 101.3, 99.1, 57.9, 21.5. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}\text{FNO}_5\text{S} [\text{M} + \text{Na}]^+$ 438.0786, Found: 438.0782.

N-((3-Chlorophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3h**. Yield: 39.3 mg, 91%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 10.47 min, t_r (minor) = 13.27 min, $ee = 96\%$. $[\alpha]_{\text{D}}^{19.3} = 30.7$ ($c = 0.84$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.53$ (d, $J = 8.2$ Hz, 2H), 7.20–6.95 (m, 6H), 6.38–6.16 (m, 3H), 6.06 (dd, $J = 13.8$, 8.7 Hz, 1H), 5.80 (s, 2H), 5.50 (d, $J = 8.9$ Hz, 1H), 2.33 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.1$, 147.7, 143.6, 142.0, 141.2, 136.6, 134.2, 129.6, 129.4, 127.4, 127.1, 127.0, 125.1, 117.4, 108.6, 101.3, 99.0, 58.0, 21.4. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}^{34,9689}\text{ClNO}_5\text{S} [\text{M} + \text{Na}]^+$ 454.0486, Found: 454.0488. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}^{36,9659}\text{ClNO}_5\text{S} [\text{M} + \text{Na}]^+$ 456.0456, Found: 456.0464.

N-((4-Chlorophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3i**. Yield: 32.4 mg, 75%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 9.97 min, t_r (minor) = 13.95 min, $ee = 94\%$. $[\alpha]_{\text{D}}^{19.3} = 20.9$ ($c = 0.59$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.54$ (d, $J = 8.2$ Hz, 2H), 7.17–7.15 (m, 2H), 7.11–7.09 (m, 4H), 6.28 (s, 1H), 6.23 (s, 1H), 6.03 (s, 1H), 5.92 (d, $J = 8.8$ Hz, 1H), 5.82 (s, 2H), 5.49 (d, $J = 8.8$ Hz, 1H), 2.35 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.0$, 147.7, 143.6, 141.3, 138.4, 136.6, 133.2, 129.4, 128.4, 128.3, 127.1, 117.7, 108.6, 101.3, 99.1, 57.9, 21.5. HRMS (ESI-

TOF): Calcd for $\text{C}_{21}\text{H}_{18}^{34,9689}\text{ClNO}_5\text{S} [\text{M} + \text{Na}]^+$ 454.0486, Found: 454.0493. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}^{36,9659}\text{ClNO}_5\text{S} [\text{M} + \text{Na}]^+$ 456.0456, Found: 456.0476.

N-((3-Bromophenyl)(6-hydroxybenzo[d][1,3]dioxol-5-yl)methyl)-4-methylbenzenesulfonamide **3j**. Yield: 30.5 mg, 64%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 8.92 min, t_r (minor) = 11.86 min, $ee = 92\%$. $[\alpha]_{\text{D}}^{26.0} = 10.4$ ($c = 0.79$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.52$ (d, $J = 8.2$ Hz, 2H), 7.27 (d, $J = 8.1$ Hz, 1H), 7.25 (s, 1H), 7.08 (tt, $J = 15.7$, 7.8 Hz, 4H), 6.38 (s, 1H), 6.28 (s, 1H), 6.24 (s, 1H), 6.11 (d, $J = 8.9$ Hz, 1H), 5.80 (d, $J = 0.8$ Hz, 2H), 5.49 (d, $J = 8.8$ Hz, 1H), 2.33 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.0$, 147.7, 143.6, 141.2, 139.0, 136.6, 131.4, 129.4, 128.7, 127.1, 121.3, 117.5, 108.6, 101.3, 99.0, 58.0, 21.5. HRMS (ESI-TOF): Calcd for $\text{C}_{21}\text{H}_{18}^{78,9183}\text{BrNO}_5\text{S} [\text{M} + \text{Na}]^+$ 497.9981, Found: 497.9990.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(3-(trifluoromethyl)phenyl)methyl)-4-methylbenzenesulfonamide **3k**. Yield: 41.9 mg, 90%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 6.69 min, t_r (minor) = 7.55 min, $ee = 96\%$. $[\alpha]_{\text{D}}^{16.3} = 19.2$ ($c = 0.88$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.55$ (d, $J = 8.3$ Hz, 2H), 7.46–7.35 (m, 3H), 7.31 (t, $J = 7.6$ Hz, 1H), 7.09 (d, $J = 8.0$ Hz, 2H), 6.30 (d, $J = 2.8$ Hz, 1H), 6.25 (s, 1H), 6.16 (dd, $J = 34.9$, 15.7 Hz, 1H), 6.06 (d, $J = 8.9$ Hz, 1H), 5.82 (dd, $J = 3.3$, 1.3 Hz, 2H), 5.58 (dd, $J = 8.6$, 3.8 Hz, 1H), 2.33 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.0$, 147.9, 143.6, 141.4, 141.0, 136.6, 133.6 (d, $J = 594.9$ Hz), 130.4, 129.4, 128.8, 127.0, 124.2 (d, $J = 4.0$ Hz), 123.9 (d, $J = 272.7$ Hz), 123.5 (d, $J = 3.0$ Hz), 117.4, 108.5, 101.3, 99.0, 58.1, 21.4. HRMS (ESI-TOF): Calcd for $\text{C}_{22}\text{H}_{18}\text{F}_3\text{NO}_5\text{S} [\text{M} + \text{Na}]^+$ 488.0750, Found: 488.0757.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(4-(trifluoromethyl)phenyl)methyl)-4-methylbenzenesulfonamide **3l**. Yield: 33.0 mg, 71%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 7.12 min, t_r (minor) = 8.80 min, $ee = 89\%$. $[\alpha]_{\text{D}}^{26.0} = 27.1$ ($c = 0.92$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.52$ (d, $J = 8.2$ Hz, 2H), 7.41 (d, $J = 8.1$ Hz, 2H), 7.29 (d, $J = 8.1$ Hz, 2H), 7.05 (d, $J = 7.9$ Hz, 2H), 6.46–6.34 (m, 1H), 6.28 (dd, $J = 14.3$, 9.2 Hz, 3H), 5.80 (s, 2H), 5.56 (d, $J = 8.9$ Hz, 1H), 2.31 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.1$, 147.8, 144.0, 143.7, 141.3, 136.6, 129.3 (d, $J = 32.3$ Hz), 129.4, 127.2, 127.1, 125.2 (d, $J = 4.0$ Hz), 124.0 (d, $J = 273.7$ Hz), 117.3, 108.5, 101.3, 99.0, 58.2, 21.3. HRMS (ESI-TOF): Calcd for $\text{C}_{22}\text{H}_{18}\text{F}_3\text{NO}_5\text{S} [\text{M} + \text{Na}]^+$ 488.0750, Found: 488.0751.

tert-Butyl 6-(Furan-2-yl(4-methylphenylsulfonamido)methyl)-benzo[d][1,3]dioxol-5-yl Carbonate **3m**. Yield: 39.0 mg, 80%, yellow oil. HPLC (chiralcel IE, hexane/*i*-PrOH = 80/20, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 27.08 min, t_r (minor) = 30.15 min, $ee = 86\%$. $[\alpha]_{\text{D}}^{10.8} = 44.3$ ($c = 0.57$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.59$ (d, $J = 8.3$ Hz, 2H), 7.21 (d, $J = 0.9$ Hz, 1H), 7.14 (d, $J = 8.0$ Hz, 2H), 6.55 (d, $J = 7.2$ Hz, 2H), 6.17 (dd, $J = 3.2$, 1.8 Hz, 1H), 6.01 (d, $J = 3.2$ Hz, 1H), 5.90 (dd, $J = 4.9$, 1.2 Hz, 2H), 5.69 (d, $J = 8.0$ Hz, 1H), 5.51 (d, $J = 8.0$ Hz, 1H), 2.36 (s, 3H), 1.48 (s, 9H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 151.5$, 151.2, 147.6, 145.2, 143.1, 142.7, 142.6, 137.3, 129.2, 127.2, 122.7, 110.3, 107.7, 104.4, 101.9, 84.1, 51.5, 27.6, 21.5. HRMS (ESI-TOF): Calcd for $\text{C}_{24}\text{H}_{25}\text{NO}_8\text{S} [\text{M} + \text{Na}]^+$ 510.1193, Found: 510.1200.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(thiophen-2-yl)methyl)-4-methylbenzenesulfonamide **3n**. Yield: 12.9 mg, 32%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 75/25, flow rate = 1.0 mL/min, $\lambda = 254$ nm), t_r (major) = 14.69 min, t_r (minor) = 20.16 min, $ee = 83\%$. $[\alpha]_{\text{D}}^{27.9} = 14.7$ ($c = 0.21$, in CH_2Cl_2). $^1\text{H NMR}$ (400 MHz, CDCl_3) $\delta = 7.61$ (d, $J = 8.3$ Hz, 2H), 7.16 (dd, $J = 3.4$, 1.3 Hz, 2H), 7.14 (s, 1H), 6.84 (dd, $J = 5.1$, 3.6 Hz, 1H), 6.71 (dd, $J = 2.4$, 1.1 Hz, 1H), 6.41 (s, 1H), 6.28 (s, 1H), 5.86 (s, 2H), 5.77 (dd, $J = 23.1$, 8.7 Hz, 2H), 5.59 (s, 1H), 2.37 (s, 3H). $^{13}\text{C NMR}$ (100 MHz, CDCl_3) $\delta = 148.04$, 147.95, 144.36, 143.47, 141.51, 136.81, 129.34, 127.21, 126.85, 125.43, 125.34, 118.39, 108.26, 101.33, 99.39, 55.04, 21.49. HRMS (ESI-TOF): Calcd for $\text{C}_{19}\text{H}_{17}\text{NO}_5\text{S}_2 [\text{M} + \text{Na}]^+$ 426.0440, Found: 426.0444.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)(naphthalen-2-yl)methyl)-4-methylbenzenesulfonamide **3o**. Yield: 23.7 mg, 53%, yellow oil.

HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, λ = 254 nm), t_r (major) = 16.314 min, t_r (minor) = 21.921 min, *ee* = 86%. $[\alpha]_D^{27.9}$ = 34.0 (*c* = 0.53, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.80–7.71 (m, 1H), 7.64 (dd, *J* = 13.6, 6.4 Hz, 2H), 7.54 (d, *J* = 8.0 Hz, 3H), 7.47–7.37 (m, 2H), 7.27 (d, *J* = 1.6 Hz, 1H), 6.99 (d, *J* = 8.2 Hz, 2H), 6.32 (s, 1H), 6.29 (s, 1H), 6.08 (s, 1H), 5.92 (dd, *J* = 8.7, 3.7 Hz, 1H), 5.85–5.76 (m, 2H), 5.72 (d, *J* = 8.7 Hz, 1H), 2.24 (s, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 148.35, 147.71, 143.43, 141.34, 136.81, 136.71, 132.99, 132.59, 129.27, 128.27, 128.03, 127.53, 127.16, 126.20, 126.10, 125.54, 125.09, 118.09, 108.68, 101.24, 99.26, 58.36, 21.36. HRMS (ESI-TOF): Calcd for C₂₅H₂₁NO₅S [M+K]⁺ 486.0772, Found: 486.0766.

N-((6-Hydroxybenzo[d][1,3]dioxol-5-yl)phenyl)methyl)benzenesulfonamide **3p**. Yield: 32.6 mg, 85%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, λ = 254 nm), t_r (major) = 10.19 min, t_r (minor) = 11.99 min, *ee* = 92%. $[\alpha]_D^{19.3}$ = 24.3 (*c* = 0.79, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.66 (d, *J* = 8.0 Hz, 2H), 7.40 (t, *J* = 6.4 Hz, 1H), 7.29 (d, *J* = 1.7 Hz, 1H), 7.25 (d, *J* = 0.6 Hz, 1H), 7.17 (d, *J* = 1.3 Hz, 5H), 6.27 (d, *J* = 11.5 Hz, 2H), 6.24–6.10 (m, 1H), 6.10–5.98 (m, 1H), 5.79 (d, *J* = 4.7 Hz, 2H), 5.59 (d, *J* = 8.6 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 148.2, 147.6, 141.2, 139.8, 139.7, 132.5, 128.7, 128.4, 127.4, 127.1, 126.9, 118.0, 108.6, 101.2, 99.1, 58.4. HRMS (ESI-TOF): Calcd for C₂₀H₁₇NO₅S [M + Na]⁺ 406.0720, Found: 406.0726.

4-Chloro-*N*-((6-hydroxybenzo[d][1,3]dioxol-5-yl)phenyl)methyl)benzenesulfonamide **3q**. Yield: 33.4 mg, 80%, yellow oil. HPLC (chiralcel ID, hexane/*i*-PrOH = 70/30, flow rate = 1.0 mL/min, λ = 254 nm), t_r (major) = 7.30 min, t_r (minor) = 9.36 min, *ee* = 95%. $[\alpha]_D^{19.3}$ = 23.3 (*c* = 0.73, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.57 (d, *J* = 8.6 Hz, 2H), 7.26–7.12 (m, 7H), 6.25 (d, *J* = 9.5 Hz, 2H), 6.04 (d, *J* = 8.9 Hz, 1H), 5.91 (s, 1H), 5.84 (d, *J* = 2.6 Hz, 2H), 5.58 (d, *J* = 8.8 Hz, 1H). ¹³C NMR (100 MHz, CDCl₃) δ = 147.9, 147.7, 141.4, 139.4, 138.9, 138.4, 128.9, 128.6, 128.5, 127.6, 126.8, 117.7, 108.7, 101.4, 99.0, 58.4. HRMS (ESI-TOF): Calcd for C₂₀H₁₆^{34,9689}CINO₅S [M + Na]⁺ 440.0330, Found: 440.0339. HRMS (ESI-TOF): Calcd for C₂₀H₁₆^{36,9659}CINO₅S [M + Na]⁺ 442.0300, Found: 442.0294.

(*R*)-*tert*-Butyl (6-(*tert*-Butoxycarbonyloxy)benzo[d][1,3]dioxol-5-yl)(3-fluorophenyl)methyl(tosyl)carbamate **4**. Yield: 59.1 mg, 99%, white foam. HPLC (chiralcel ID, hexane/*i*-PrOH = 80/20, flow rate = 1.0 mL/min, λ = 254 nm), t_r (major) = 9.43 min, t_r (minor) = 10.82 min, *ee* = 95%. $[\alpha]_D^{27.3}$ = -31.3 (*c* = 3.51, in CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ = 7.65 (d, *J* = 8.3 Hz, 2H), 7.24–7.10 (m, 3H), 6.96–6.73 (m, 5H), 6.63 (s, 1H), 5.89 (d, *J* = 2.5 Hz, 2H), 2.32 (s, 3H), 1.32 (s, 9H), 1.11 (s, 9H). ¹³C NMR (100 MHz, CDCl₃) δ = 161.6 (d, *J* = 246.4 Hz), 150.4, 149.7, 146.6, 144.3, 143.3, 142.6, 140.7 (d, *J* = 8.1 Hz), 135.7, 128.6 (d, *J* = 8.1 Hz), 128.1, 127.6, 122.3, 122.2 (d, *J* = 3.0 Hz), 113.8 (d, *J* = 23.2 Hz), 112.9 (d, *J* = 21.2 Hz), 108.7, 102.8, 100.9, 83.8, 82.8, 57.1, 26.7, 26.4, 20.6. HRMS (ESI-TOF): Calcd for C₃₁H₃₄FNO₅S [M + Na]⁺ 638.1831, Found: 638.1841.

ASSOCIATED CONTENT

Supporting Information

Full optimization details, ¹H and ¹³C NMR spectra, HPLC analyses for all the products, and X-ray crystal data of compound **4** (CIF) are available. This material is available free of charge via the Internet at <http://pubs.acs.org>.

AUTHOR INFORMATION

Corresponding Author

*E-mail: xmfeng@scu.edu.cn (X.F.).

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

We appreciate the National Natural Science Foundation of China (Nos. 21021001, 21290182, 21172151), the Ministry of Education (No. 20110181130014), and the Basic Research

Program of China (973 Program: 2011CB808600) for financial support.

REFERENCES

- (1) (a) Dibwe, D. F.; Awale, S.; Kadota, S.; Morita, H.; Tezuka, Y. *Bioorg. Med. Chem.* **2013**, *21*, 7663. (b) Beekman, A. M.; Barrow, R. A. *J. Org. Chem.* **2014**, *79*, 1017. (c) Hugo, A. G.; Jimena, M. M.; Gladys, M. C.; Carlos, E. T.; Carlos, R. P. *Bioorg. Med. Chem. Lett.* **2014**, *24*, 760. (d) Tsai, W. J.; Shen, C. C.; Tsai, T. H.; Lin, L. C. *J. Nat. Prod.* **2014**, *77*, 125.
- (2) (a) Bräse, S.; Encinas, A.; Keck, J.; Nising, C. F. *Chem. Rev.* **2009**, *109*, 3903. (b) Lavecchia, A.; Giovanni, C. D.; Cerchia, C.; Russo, A.; Russo, G.; Novellino, E. *J. Med. Chem.* **2013**, *56*, 2861. (c) Scott, J. D.; Williams, R. M. *Chem. Rev.* **2002**, *102*, 1669. (d) Hitotsuyanagi, Y.; Ichihara, Y.; Takeya, K.; Itokawa, H. *Tetrahedron Lett.* **1994**, *35*, 9401.
- (3) (a) Olah, G. A. *Friedel–Crafts Chemistry*; Wiley: New York, 1973. (b) Roberts, R. M.; Khalaf, A. A. *Friedel–Crafts Alkylation Chemistry: A Century of Discovery*; Wiley-Interscience: New York, 1984.
- (4) For reviews on asymmetric aza-Friedel–Crafts reaction: You, S.-L.; Cai, Q.; Zeng, M. *Chem. Soc. Rev.* **2009**, *38*, 2190. For selected examples of asymmetric aza-Friedel–Crafts reactions: (a) Kang, Q.; Zheng, X. J.; You, S.-L. *Chem.—Eur. J.* **2008**, *14*, 3539. (b) Enders, D.; Seppelt, M.; Beck, T. *Adv. Synth. Catal.* **2010**, *352*, 1413. (c) Husmann, R.; Sugiono, E.; Mersmann, S.; Raabe, G.; Rueping, M.; Bolm, C. *Org. Lett.* **2011**, *13*, 1044. (d) Li, G. X.; Qu, J. *Chem. Commun.* **2012**, *48*, 5518. (e) Zhang, K. F.; Nie, J.; Guo, R.; Zheng, Y.; Ma, J. *Adv. Synth. Catal.* **2013**, *355*, 3597. (f) Wang, S. G.; You, S.-L. *Angew. Chem., Int. Ed.* **2014**, *53*, 2194.
- (5) For selected aza-Friedel–Crafts reactions of indoles, see: (a) Terada, M.; Yokoyama, S.; Sorimachi, K.; Uruguchi, D. *Adv. Synth. Catal.* **2007**, *349*, 1863. (b) Zhou, S.-L.; Li, J.-L.; Dong, L.; Chen, Y.-C. *Org. Lett.* **2011**, *13*, 5874. (c) Feng, J. C.; Yan, W. J.; Wang, D.; Li, P.; Sun, Q. T.; Wang, R. *Chem. Commun.* **2012**, *48*, 8003. (d) Yang, H. H.; Cui, B.; Wu, G. P.; Miao, Z. W.; Chen, R. Y. *Tetrahedron* **2012**, *68*, 4830.
- (6) For selected aza-Friedel–Crafts reactions of pyrroles, see: (a) Nakamura, S.; Sakurai, Y.; Nakashima, H.; Shibata, N.; Toru, T. *Synlett.* **2009**, 1639. (b) He, Y. W.; Lin, M. H.; Li, Z. M.; Liang, X. T.; Li, G. L.; Antilla, J. C. *Org. Lett.* **2011**, *13*, 4490.
- (7) For selected aza-Friedel–Crafts reactions of naphthols, see: (a) Liu, G. X.; Li, S. L.; Zhang, H.; Zhang, T. Z.; Wang, W. *Org. Lett.* **2011**, *13*, 828. (b) Chauhan, P.; Chimni, S. S. *Eur. J. Org. Chem.* **2011**, 1636. (c) Niu, L.-F.; Xin, Y.-C.; Wang, R.-L.; Jiang, F.; Xu, P.-F.; Hui, X.-P. *Synlett* **2010**, 765.
- (8) Chauhan, P.; Chimni, S. S. *Tetrahedron Lett.* **2013**, *54*, 4613.
- (9) For reviews and examples of *N,N'*-dioxide–metal complexes in asymmetric reactions, see: (a) Liu, X. H.; Lin, L. L.; Feng, X. M. *Acc. Chem. Res.* **2011**, *44*, 574. (b) Liu, X. H.; Lin, L. L.; Feng, X. M. *Org. Chem. Front.* **2014**, *1*, 298. (c) Zhou, L.; Liu, X. H.; Ji, J.; Zhang, Y. H.; Hu, X. L.; Lin, L. L.; Feng, X. M. *J. Am. Chem. Soc.* **2012**, *134*, 17023. (d) Li, W.; Liu, X. H.; Hao, X. Y.; Cai, Y. F.; Lin, L. L.; Feng, X. M. *Angew. Chem., Int. Ed.* **2012**, *51*, 8644. (e) Zheng, K.; Lin, L. L.; Feng, X. M. *Acta Chim. Sin.* **2012**, *70*, 1785. (f) Shen, K.; Liu, X. H.; Wang, G.; Lin, L. L.; Feng, X. M. *Angew. Chem., Int. Ed.* **2011**, *50*, 4684.
- (10) For selected reactions using water or alcohols as additives, see: (a) Shimada, Y.; Matsuoka, Y.; Irie, R.; Katsuki, T. *Synlett* **2004**, 57. (b) Onitsuka, S.; Matsuoka, Y.; Irie, R.; Katsuki, T. *Chem. Lett.* **2003**, *32*, 974. (c) Matsuoka, Y.; Irie, R.; Katsuki, T. *Chem. Lett.* **2003**, *32*, 584.
- (11) CCDC 1020310 (**4**) contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
- (12) (a) Girard, C.; Kagan, H. B. *Angew. Chem., Int. Ed.* **1998**, *37*, 2922. (b) Kagan, H. B. *Adv. Synth. Catal.* **2001**, *343*, 227. (c) Satyanarayana, T.; Abraham, S.; Kagan, H. B. *Angew. Chem., Int. Ed.* **2009**, *48*, 456.

(13) X-ray single-crystal structure of *N,N'*-dioxide–Sc(III): Liu, Y. L.; Shang, D. J.; Zhou, X.; Liu, X. H.; Feng, X. M. *Chem.—Eur. J.* **2009**, *15*, 2055.

(14) The hydroxyl group on the sesamol **2** was crucial in the catalysis. No corresponding products were observed when the hydroxyl group on the sesamol **2** was protected. See the Supporting Information for details.

(15) (a) Shibasaki, M.; Yoshikawa, N. *Chem. Rev.* **2002**, *102*, 2187.

(b) Kobayashi, S.; Sugiura, M.; Kitagawa, H.; Lam, W. W.-L. *Chem. Rev.* **2002**, *102*, 2227.

(16) For selected aza-Friedel–Crafts reactions of imines activated by acid, see: (a) Kinoshita, H.; Ingham, O. J.; Ong, W. W.; Beeler, A. B.; J. A, P., Jr. *J. Am. Chem. Soc.* **2010**, *132*, 6412. (b) Uruguchi, D.; Sorimachi, K.; Terada, M. *J. Am. Chem. Soc.* **2004**, *126*, 11804. (c) Zhang, K.-F.; Nie, J.; Guo, R.; Zheng, Y.; Ma, J.-A. *Adv. Synth. Catal.* **2013**, *355*, 3497. (d) Courant, T.; Kumarn, S.; He, L.; Retailleau, P.; Masson, G. *Adv. Synth. Catal.* **2013**, *355*, 836.